Latest news

• Bayer pins hopes on five potential blockbusters

  €39.8bn for 2012. ... This helped overcome a decline in sales of the Yaz contraceptive franchise, which lost patent exclusivity during 2012.

• Actavis sales rise but profits slump as Lipitor effect recedes

  Generics company Actavis - formerly Watson Pharma reported revenue growth of 13 per cent to $1.75bn in the last three months of 2012 in its first set of results since the merger. ... Actavis stopped selling its generic atorvastatin last month because of

• Shire weathers generic Adderall XR challenge

  Shire posted revenue growth of 5 per cent for the fourth quarter of 2012 despite facing full generic competition for its attention deficit-hyperactivity disorder ( ADHD) drug Adderall XR ( amphetamine and dextroamphetamine). ... As we look forward to the

• Lundbeck looks to new products as Lexapro slumps

  Lundbeck managed to offset dwindling US sales of its antidepressant former blockbuster Lexapro with gains for new products in the fourth quarter of 2012, reporting sales that were flat at 3.85bn ... The big news for the company in 2012 was the loss of

• GSK planning restructuring in Europe as earnings fall

  GlaxoSmithKline announced another wave of restructuring yesterday - focused on its European operations - after reporting sales and operating profit fell in 2012. ... Sir Andrew said on the firm's annual results conference call that the programme will